These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Dikmen ZG; Gellert GC; Jackson S; Gryaznov S; Tressler R; Dogan P; Wright WE; Shay JW Cancer Res; 2005 Sep; 65(17):7866-73. PubMed ID: 16140956 [TBL] [Abstract][Full Text] [Related]
4. Oligonucleotide N3'-->P5' phosphoramidates as efficient telomerase inhibitors. Herbert BS; Pongracz K; Shay JW; Gryaznov SM Oncogene; 2002 Jan; 21(4):638-42. PubMed ID: 11850790 [TBL] [Abstract][Full Text] [Related]
5. Imetelstat (a telomerase antagonist) exerts off‑target effects on the cytoskeleton. Mender I; Senturk S; Ozgunes N; Akcali KC; Kletsas D; Gryaznov S; Can A; Shay JW; Dikmen ZG Int J Oncol; 2013 May; 42(5):1709-15. PubMed ID: 23545855 [TBL] [Abstract][Full Text] [Related]
6. Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Herbert BS; Gellert GC; Hochreiter A; Pongracz K; Wright WE; Zielinska D; Chin AC; Harley CB; Shay JW; Gryaznov SM Oncogene; 2005 Aug; 24(33):5262-8. PubMed ID: 15940257 [TBL] [Abstract][Full Text] [Related]
7. Oligonucleotide conjugate GRN163L targeting human telomerase as potential anticancer and antimetastatic agent. Gryaznov SM; Jackson S; Dikmen G; Harley C; Herbert BS; Wright WE; Shay JW Nucleosides Nucleotides Nucleic Acids; 2007; 26(10-12):1577-9. PubMed ID: 18066830 [TBL] [Abstract][Full Text] [Related]
8. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Gellert GC; Dikmen ZG; Wright WE; Gryaznov S; Shay JW Breast Cancer Res Treat; 2006 Mar; 96(1):73-81. PubMed ID: 16319992 [TBL] [Abstract][Full Text] [Related]
9. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Djojosubroto MW; Chin AC; Go N; Schaetzlein S; Manns MP; Gryaznov S; Harley CB; Rudolph KL Hepatology; 2005 Nov; 42(5):1127-36. PubMed ID: 16114043 [TBL] [Abstract][Full Text] [Related]
10. Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Akiyama M; Hideshima T; Shammas MA; Hayashi T; Hamasaki M; Tai YT; Richardson P; Gryaznov S; Munshi NC; Anderson KC Cancer Res; 2003 Oct; 63(19):6187-94. PubMed ID: 14559802 [TBL] [Abstract][Full Text] [Related]
11. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Asai A; Oshima Y; Yamamoto Y; Uochi TA; Kusaka H; Akinaga S; Yamashita Y; Pongracz K; Pruzan R; Wunder E; Piatyszek M; Li S; Chin AC; Harley CB; Gryaznov S Cancer Res; 2003 Jul; 63(14):3931-9. PubMed ID: 12873987 [TBL] [Abstract][Full Text] [Related]
12. Oligonucleotide n3'-->p5' phosphoramidates and thio-phoshoramidates as potential therapeutic agents. Gryaznov SM Chem Biodivers; 2010 Mar; 7(3):477-93. PubMed ID: 20232321 [TBL] [Abstract][Full Text] [Related]
13. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Hochreiter AE; Xiao H; Goldblatt EM; Gryaznov SM; Miller KD; Badve S; Sledge GW; Herbert BS Clin Cancer Res; 2006 May; 12(10):3184-92. PubMed ID: 16707619 [TBL] [Abstract][Full Text] [Related]
14. Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells. Burchett KM; Yan Y; Ouellette MM PLoS One; 2014; 9(1):e85155. PubMed ID: 24409321 [TBL] [Abstract][Full Text] [Related]
15. Specific telomere dysfunction induced by GRN163L increases radiation sensitivity in breast cancer cells. Gomez-Millan J; Goldblatt EM; Gryaznov SM; Mendonca MS; Herbert BS Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):897-905. PubMed ID: 17175117 [TBL] [Abstract][Full Text] [Related]
16. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects. Kelland LR Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745 [TBL] [Abstract][Full Text] [Related]
19. Telomerase inhibitor imetelstat has preclinical activity across the spectrum of non-small cell lung cancer oncogenotypes in a telomere length dependent manner. Frink RE; Peyton M; Schiller JH; Gazdar AF; Shay JW; Minna JD Oncotarget; 2016 May; 7(22):31639-51. PubMed ID: 27192120 [TBL] [Abstract][Full Text] [Related]